Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kringle Pharma, Inc.

Latest From Kringle Pharma, Inc.

Deal Watch: Focus Placed On Psoriasis With Recent Purdue, Sienna Deals

Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.

Deals M & A

Asia Beat: Japan's bioventure sector needs decisive action

Japan has been attempting to get its bioventure sector off the ground for as long as many in the industry can remember, certainly since I first started coming to the country more than 20 years ago. But progress continues to be glacially slow.

Cancer Orthopedics

Scrip Asia 100 - Asia's shining stars

The Scrip Asia 100 analysis identifies 100 of the most influential players on the Asia-Pacific life sciences scene. Our shining stars are 10 of Asia's visionary leaders from the worlds of pharma business and science.

Dermatology Immune Disorders

Europe venture to take on Kringle's lead project

Kringle Pharma has set up its first overseas operation, a European subsidiary which will progress the clinical development of its lead recombinant hepatic growth factor therapy.

Dermatology Wound Healing & Tissue Repair
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Kringle Pharma Europe AB